Life4me+ news story
In the Phase 3 study MK-8591A-053, investigators compared the investigational once-daily two-drug regimen doravirine/islatravir (DOR/ISL 100/0.25 mg) with the established three-drug single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in treatment-naïve adults.
The central question was straightforward but clinically relevant: can a non-INSTI two-drug regimen deliver virologic efficacy comparable to one of the most widely used integrase inhibitor–based standards?
The Week 48 results demonstrate that DOR/ISL (100/0.25 mg) is noninferior to BIC/FTC/TAF for initial treatment of HIV-1, with high rates of viral suppression, comparable immune recovery, and a similar safety profile.
These findings do not displace integrase inhibitor–based therapy as a standard of care. Rather, they broaden the therapeutic landscape. In contemporary HIV medicine, flexibility is increasingly important. Not every patient requires the same mechanism, and not every clinical situation favors an integrase-based approach.
The value of this study lies in diversification. It confirms that a non-INSTI two-drug regimen can achieve control comparable to a three-drug standard in a globally representative, treatment-naïve population.
In an era where treatment goals remain unchanged — durable viral suppression, immune recovery, and long-term safety — expanding validated options is itself progress.
Read the full news story here.
View all Life4me+ reports from CROI 2026
SEE ALSO:
View all aidsmap reports from CROI 2026
Source : Life4me+
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.